Literature DB >> 18414385

The endocannabinoid system in brain reward processes.

M Solinas1, S R Goldberg, D Piomelli.   

Abstract

Food, drugs and brain stimulation can serve as strong rewarding stimuli and are all believed to activate common brain circuits that evolved in mammals to favour fitness and survival. For decades, endogenous dopaminergic and opioid systems have been considered the most important systems in mediating brain reward processes. Recent evidence suggests that the endogenous cannabinoid (endocannabinoid) system also has an important role in signalling of rewarding events. First, CB(1) receptors are found in brain areas involved in reward processes, such as the dopaminergic mesolimbic system. Second, activation of CB(1) receptors by plant-derived, synthetic or endogenous CB(1) receptor agonists stimulates dopaminergic neurotransmission, produces rewarding effects and increases rewarding effects of abused drugs and food. Third, pharmacological or genetic blockade of CB(1) receptors prevents activation of dopaminergic neurotransmission by several addictive drugs and reduces rewarding effects of food and these drugs. Fourth, brain levels of the endocannabinoids anandamide and 2-arachidonoylglycerol are altered by activation of reward processes. However, the intrinsic activity of the endocannabinoid system does not appear to play a facilitatory role in brain stimulation reward and some evidence suggests it may even oppose it. The influence of the endocannabinoid system on brain reward processes may depend on the degree of activation of the different brain areas involved and might represent a mechanism for fine-tuning dopaminergic activity. Although involvement of the various components of the endocannabinoid system may differ depending on the type of rewarding event investigated, this system appears to play a major role in modulating reward processes.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18414385      PMCID: PMC2442437          DOI: 10.1038/bjp.2008.130

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  210 in total

1.  CB1 cannabinoid receptors and on-demand defense against excitotoxicity.

Authors:  Giovanni Marsicano; Sharon Goodenough; Krisztina Monory; Heike Hermann; Matthias Eder; Astrid Cannich; Shahnaz C Azad; Maria Grazia Cascio; Silvia Ortega Gutiérrez; Mario van der Stelt; Maria Luz López-Rodriguez; Emilio Casanova; Günther Schütz; Walter Zieglgänsberger; Vincenzo Di Marzo; Christian Behl; Beat Lutz
Journal:  Science       Date:  2003-10-03       Impact factor: 47.728

Review 2.  The molecular logic of endocannabinoid signalling.

Authors:  Daniele Piomelli
Journal:  Nat Rev Neurosci       Date:  2003-11       Impact factor: 34.870

3.  Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors.

Authors:  Z Járai; J A Wagner; K Varga; K D Lake; D R Compton; B R Martin; A M Zimmer; T I Bonner; N E Buckley; E Mezey; R K Razdan; A Zimmer; G Kunos
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-23       Impact factor: 11.205

4.  Cannabinoid modulation of the reinforcing and motivational properties of heroin and heroin-associated cues in rats.

Authors:  Taco J De Vries; Judith R Homberg; Rob Binnekade; Halfdan Raasø; Anton N M Schoffelmeer
Journal:  Psychopharmacology (Berl)       Date:  2003-04-01       Impact factor: 4.530

Review 5.  Role of endogenous cannabinoids in synaptic signaling.

Authors:  Tamas F Freund; Istvan Katona; Daniele Piomelli
Journal:  Physiol Rev       Date:  2003-07       Impact factor: 37.312

6.  SR141716A reduces the reinforcing properties of heroin but not heroin-induced increases in nucleus accumbens dopamine in rats.

Authors:  Stéphanie Caillé; Loren H Parsons
Journal:  Eur J Neurosci       Date:  2003-12       Impact factor: 3.386

7.  The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis.

Authors:  Daniela Cota; Giovanni Marsicano; Matthias Tschöp; Yvonne Grübler; Cornelia Flachskamm; Mirjam Schubert; Dorothee Auer; Alexander Yassouridis; Christa Thöne-Reineke; Sylvia Ortmann; Federica Tomassoni; Cristina Cervino; Enzo Nisoli; Astrid C E Linthorst; Renato Pasquali; Beat Lutz; Günter K Stalla; Uberto Pagotto
Journal:  J Clin Invest       Date:  2003-08       Impact factor: 14.808

Review 8.  Cannabinoids: reward, dependence, and underlying neurochemical mechanisms--a review of recent preclinical data.

Authors:  Gianluigi Tanda; Steven R Goldberg
Journal:  Psychopharmacology (Berl)       Date:  2003-06-24       Impact factor: 4.530

Review 9.  Cannabis and alcohol--a close friendship.

Authors:  Raphael Mechoulam; Linda Parker
Journal:  Trends Pharmacol Sci       Date:  2003-06       Impact factor: 14.819

10.  Cannabinoid receptor and WIN 55 212-2-stimulated [35S]-GTPgammaS binding in the brain of mu-, delta- and kappa-opioid receptor knockout mice.

Authors:  Fernando Berrendero; Victoria Mendizábal; Patricia Murtra; Brigitte L Kieffer; Rafael Maldonado
Journal:  Eur J Neurosci       Date:  2003-10       Impact factor: 3.386

View more
  107 in total

Review 1.  Pharmacology of signaling induced by dopamine D(1)-like receptor activation.

Authors:  Ashiwel S Undieh
Journal:  Pharmacol Ther       Date:  2010-06-12       Impact factor: 12.310

Review 2.  Animal models of cannabinoid reward.

Authors:  Leigh V Panlilio; Zuzana Justinova; Steven R Goldberg
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

3.  Cannabinoid-1 receptor antagonist rimonabant (SR141716) increases striatal dopamine D2 receptor availability.

Authors:  Cleo L Crunelle; Elsmarieke van de Giessen; Sybille Schulz; Louk J M J Vanderschuren; Kora de Bruin; Wim van den Brink; Jan Booij
Journal:  Addict Biol       Date:  2011-09-29       Impact factor: 4.280

4.  Endocannabinoids shape accumbal encoding of cue-motivated behavior via CB1 receptor activation in the ventral tegmentum.

Authors:  Erik B Oleson; Michael V Beckert; Joshua T Morra; Carien S Lansink; Roger Cachope; Rehab A Abdullah; Amy L Loriaux; Dustin Schetters; Tommy Pattij; Mitchell F Roitman; Aron H Lichtman; Joseph F Cheer
Journal:  Neuron       Date:  2012-01-26       Impact factor: 17.173

5.  Behavioral effects of psychostimulants in mutant mice with cell-type specific deletion of CB2 cannabinoid receptors in dopamine neurons.

Authors:  Ana Canseco-Alba; Norman Schanz; Branden Sanabria; Juan Zhao; Zhicheng Lin; Qing-Rong Liu; Emmanuel S Onaivi
Journal:  Behav Brain Res       Date:  2018-11-30       Impact factor: 3.332

6.  Dopaminergic augmentation of delta-9-tetrahydrocannabinol (THC) discrimination: possible involvement of D(2)-induced formation of anandamide.

Authors:  Marcello Solinas; Gianluigi Tanda; Carrie E Wertheim; Steven R Goldberg
Journal:  Psychopharmacology (Berl)       Date:  2010-02-24       Impact factor: 4.530

7.  Cannabinoid facilitation of behavioral and biochemical hedonic taste responses.

Authors:  M A De Luca; M Solinas; Z Bimpisidis; S R Goldberg; G Di Chiara
Journal:  Neuropharmacology       Date:  2011-11-02       Impact factor: 5.250

8.  Song-associated reward correlates with endocannabinoid-related gene expression in male European starlings (Sturnus vulgaris).

Authors:  Allison H Hahn; Devin P Merullo; Jeremy A Spool; Caroline S Angyal; Sharon A Stevenson; Lauren V Riters
Journal:  Neuroscience       Date:  2017-01-29       Impact factor: 3.590

9.  Adolescent Δ(9)-Tetrahydrocannabinol Exposure Alters WIN55,212-2 Self-Administration in Adult Rats.

Authors:  Maria Scherma; Christian Dessì; Anna Lisa Muntoni; Salvatore Lecca; Valentina Satta; Antonio Luchicchi; Marco Pistis; Leigh V Panlilio; Liana Fattore; Steven R Goldberg; Walter Fratta; Paola Fadda
Journal:  Neuropsychopharmacology       Date:  2015-09-21       Impact factor: 7.853

10.  Fatty acid amide hydrolase inhibition heightens anandamide signaling without producing reinforcing effects in primates.

Authors:  Zuzana Justinova; Regina A Mangieri; Marco Bortolato; Svetlana I Chefer; Alexey G Mukhin; Jason R Clapper; Alvin R King; Godfrey H Redhi; Sevil Yasar; Daniele Piomelli; Steven R Goldberg
Journal:  Biol Psychiatry       Date:  2008-09-23       Impact factor: 13.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.